Study Title
Medical Experiment - Assessment of Efficacy & Safety of Local, Targeted Therapy With Neuropeptide Labelled With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) as Supplementary Therapy in Glioma (WHO G3-G4) Progression
Study Details
Description:
The aim of this study is to assess the efficacy and safety of local targeted therapy with [225Ac]Ac-DOTA-SP in recurrent glioblastoma.
Sponsor:
Medical University of Warsaw
Contacts:
Przemysław Kunert (Professor)przemyslaw.kunert@wum.edu.pl
+48 22 599 2575
Government Study Link:
NCT06975332 - Click here to see study onClinicalTrials.gov
Drug Details
[225Ac]Ac-DOTA-SP
Isotope(s):
- ACTINIUM-225
ACTINIUM-225
Radioisotope: Ac-225
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 9.9 Days
Decay Mode: ALPHA, GAMMA
Energy: 5.8-8.4 MeV
Range: 47-85 micrometers
Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
Status: Clinical Trials Only
Target(s):
- Substance P
Chelator: DOTA
